Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Hydrochloride Liposome in advanced HER2 negative breast cancer
NCT04927481Phase 2Terminated
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2021
- Primary completion
- Jan 2023
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of mitoxantrone hydrochloride liposome in breast cancer, sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Jun 2021; status: terminated.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04927481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927481.